Evidence map›Paper›PMID 41616062›Full record

ArticleScience advances2026

Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease.

Zhen Zhang, Richard J Lobb, Paul Tooney, Jing Wang, Rebecca Lane, Quan Zhou, Xueming Niu, Sam Faulkner, Oun Al-Iedani, Bryan W Day and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhen ZhangAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-5766-3468
Richard J LobbAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-9548-8843
Paul TooneySchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.ORCID 0000-0003-3745-4367
Jing WangAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-6080-7998
Rebecca LaneAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-7650-389X
Quan ZhouAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-3267-6246
Xueming NiuAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0009-0007-3225-985X
Sam FaulknerSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.ORCID 0000-0002-4732-8252
Oun Al-IedaniSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
Bryan W DayCancer Research Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, QLD 4006, Australia.ORCID 0000-0002-8948-9089
Simon PuttickAdvanCell Pty Ltd., Queensland Centre for Advanced Technologies, Brisbane, QLD 4069, Australia.
Stephen RoseAdvanCell Pty Ltd., Queensland Centre for Advanced Technologies, Brisbane, QLD 4069, Australia.
Mike FayMark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, Newcastle, NSW 2308, Australia.
Matt TrauAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-5516-1280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessing therapeutic response in glioblastoma (GBM) is a major factor limiting the clinical development of effective therapies. The intracranial location limits serial biopsies and only provides an intermittent view of the tumor molecular profile from the initial resection. Liquid biopsy techniques, specifically small extracellular vesicle (sEV) analysis, have the potential to overcome these limitations by providing a window into the brain using peripheral blood. To address the need for monitoring tumor evolution and therapeutic resistance, we developed a GBM biomarker panel (ATPase subunit beta-2, excitatory amino acid transporter 2, CD24, CD44, CD133, and epidermal growth factor receptor) for multiplexed profiling of sEVs using an advanced GBM Extracellular Vesicle Monitoring Phenotypic Analyzer Chip. We successfully tracked patient response to treatment by monitoring changes in glioma stem cell markers on circulating sEVs. We propose that these results provide a strong rationale for using GBM sEVs as a serial monitoring tool in the future clinical management of patients with GBM.

Indexed as

Brain NeoplasmsExtracellular VesiclesGlioblastomaNanotechnologyNeoplasm Recurrence, LocalNeoplastic Stem CellsBiomarkers, TumorCell Line, TumorHumansLiquid BiopsyBiomarkers, Tumor

Identifiers

PMID41616062
PMCPMC12857736

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.